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Abstract
Background: Total circulating soluble receptor for advanced glycation endproducts (sRAGE) and
a more defined endogenous secretory splice variant of the receptor (esRAGE) were shown to be
associated with different markers of cardiovascular risk in patients with diabetes. Since previous
data were partly divergent, the aim of this study was to compare sRAGE and esRAGE in a head-
to-head analysis in patients with type 2 diabetes (T2DM) with albuminuria.
Methods: sRAGE and esRAGE were studied in plasma of 110 T2DM patients using enzyme-linked
immunosorbant assays (ELISA) detecting either sRAGE or esRAGE only. Both sRAGE and esRAGE
were compared with regard to applicability as markers for vascular disease and glucose control in
T2DM.
Results: In bivariate analysis, sRAGE correlated with age (R = 0.22, p = 0.02) and the 24 hour
albumin excretion rate (R = 0.18, p = 0.05), while esRAGE correlated positively with age only (R
= 0.23, p = 0.02). In contrast to previous reports, neither sRAGE nor esRAGE correlated with
glucose control or intima-media-thickness (IMT) as a predictor of macrovascular disease. In
multivariate regression models, the associations between sRAGE and albuminuria as well as
esRAGE and age were shown to be independent of glucose control, diabetes duration, body-mass
index, glomerular filtration rate, blood pressure and gender.
Conclusion:  This is the first study comparing sRAGE and esRAGE as markers of vascular
complications in patients with T2DM. sRAGE but not esRAGE is independently associated with
albuminuria in these patients while neither sRAGE nor esRAGE are associated with markers of
glucose control or macrovascular disease.
Background
Soluble forms of the receptor for advanced glycation end-
products (sRAGE) were previously shown to appear in
human blood and to be associated with glucose control as
well as vascular risk factors in diabetes mellitus and the
metabolic syndrome [1-6]. Plasma sRAGE consists of an
Published: 7 March 2007
Cardiovascular Diabetology 2007, 6:9 doi:10.1186/1475-2840-6-9
Received: 3 January 2007
Accepted: 7 March 2007
This article is available from: http://www.cardiab.com/content/6/1/9
© 2007 Humpert et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Cardiovascular Diabetology 2007, 6:9 http://www.cardiab.com/content/6/1/9
Page 2 of 5
(page number not for citation purposes)
endogenous splice variant of RAGE lacking the transmem-
brane domain of the receptor (esRAGE) [7] as well as pro-
teolytically cleaved forms shed into the bloodstream by
action of extracellular metalloproteinases [8,9]. Both
sRAGE and esRAGE were shown to act as decoys binding
inflammatory RAGE ligands like advanced glycation end-
products (AGEs) that accumulate in diabetes mellitus
[1,7,9,10]. It is speculated, that the soluble forms of RAGE
might counteract inflammatory reflexes triggered by
RAGE ligands such as AGEs, S100 proteins and HMGB1
[1]. However, it seems questionable that the circulating
forms of RAGE exert a biological effect, since the sRAGE
concentrations found in plasma are ~ 1000 times lower
than needed for the binding of AGEs [10]. Nevertheless,
associations of sRAGE and esRAGE with different aspects
of metabolic, vascular and autoimmune disease might
make them valuable risk markers [1-6,11,12].
Two ELISA assays for the detection of circulating RAGE are
commercially available using antibodies that detect total
circulating sRAGE or recognize esRAGE only [13]. The
previously published studies using these assays reported
inconsistent data with respect to the association of sRAGE
and esRAGE with diabetes and glucose control. While one
study detected increased levels of sRAGE [3], another
study described decreased levels of esRAGE in patients
with type 1 diabetes [5]. Likewise, esRAGE was associated
with markers of glucose control in one study [6] while a
correlation of sRAGE with measures of glucose control
was missing in another study of patients with type 2 dia-
betes [4]. These reports focussed on associations of either
esRAGE or total sRAGE with disease markers, yet, it seems
likely that sRAGE and esRAGE are distinct markers since
the secretion of esRAGE is a consequence of RAGE mRNA
processing [7]. In contrast, sRAGE is a sum of esRAGE and
RAGE most likely shed upon digestion by metalloprotein-
ase action on the cellular surface [1,8]. Hence, we con-
ducted a head-to-head analysis in patients with T2DM
and albuminuria to compare associations of both total
sRAGE and esRAGE with markers of glucose control and
vascular risk.
Methods
The study was approved by the local ethics committee;
110 T2DM patients were recruited from family practices
being referred to our diabetes outpatient clinic for special-
ist treatment after giving written consent. For eligibility,
patients had to be tested positive for albuminuria in two
separate spontaneous urine samples (> 20 mg/dl albu-
min). Patient characteristics are given in Table 1. 24-hour
urine samples were collected on three consecutive days
and the mean of albumin excretion was taken for statisti-
cal evaluation. All blood values as well as ambulatory 24-
hour blood pressure values (given as mean of 24 hours)
were taken on the day of study entrance. Glomerular fil-
tration rate (GFR) was estimated using the Cockroft-Gault
formula [14]. IMT was detected non-invasively in the end-
diastolic phase of the heart cycle in the far wall of the com-
mon carotid artery approximately 2 cm distal of the
carotid bulb on both sides using high resolution ultra-
sound. 4 measurements were taken on each side and the
mean was calculated for statistical analysis. Total sRAGE
antigen (R&D Systems, Wiesbaden, Germany) and
esRAGE (B-Bridge International, Sunnyvale, USA) antigen
were detected in plasma in duplicates by Elisa according
to the manufacturer's instructions. For statistical evalua-
tion, variables were correlated using Spearman's Coeffi-
cient. A stepwise multivariate linear regression model was
calculated to detect independent associations of age, gen-
der, diabetes duration, BMI, HbA1c, fasting glucose, GFR,
mean 24 h blood pressure and 24 hour albumin excretion
with sRAGE and esRAGE levels. p ≥ 0.1 for F-values was
taken as criterion for exclusion of variables. Albumin
excretion, sRAGE and esRAGE variables were not nor-
mally distributed and log-transformed for multivariate
analysis. SPSS 11.0 software was used for all statistical
testing (SPSS, Chicago, Illinois, USA).
Results
sRAGE and esRAGE concentrations were detected at 1326
± 621 pg/ml and 269 ± 26 pg/ml respectively; sRAGE and
esRAGE were significantly and positively correlated (R =
0.57, p < 0.001; Fig. 1a). Multivariate adjustment in a
stepwise regression model including esRAGE, age, gender,
body-mass-index, albumin excretion rate and HbA1c
showed an independent association for esRAGE with
sRAGE only. The model applied explained ~ 34% of the
variation in total sRAGE (β = 0.58, p < 0.001, R2 = 0.34;
not shown). In bivariate analysis, sRAGE correlated with
age (R = 0.22, p = 0.02) and the 24 hour albumin excre-
tion rate (R = 0.18, p = 0.05; Table 1) while esRAGE corre-
lated positively with age only (R = 0.23, p = 0.02; Table 1).
In multivariate regression models, the associations
between sRAGE and 24 hour albumin excretion (β = 0.22,
p = 0.02; Table 1) as well as esRAGE and age (β = 0.24, p
= 0.01, Table 1) were independent of glucose control, dia-
betes duration, body-mass-index, glomerular filtration
rate, blood pressure and gender. However, in contrast to
previous reports [2,3,5], in our cohort neither sRAGE nor
esRAGE correlated significantly with glucose control
(Table 1) or IMT as a predictor of macrovascular disease
(Figure 1b,c). Noteworthy, neither subtraction of esRAGE
from sRAGE nor the esRAGE/sRAGE ratio resulted in sig-
nificant associations with albuminuria, IMT or markers of
glucose control (not shown). In addition, sRAGE and
esRAGE did not correlate with the glomerular filtration
rate and the latter did not have any influence on associa-
tions of sRAGE and esRAGE with markers of disease stud-
ied in the multivariate model (Table 1). Patients treated
with angiotensin converting enzyme (ACE) – inhibitors orCardiovascular Diabetology 2007, 6:9 http://www.cardiab.com/content/6/1/9
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angiotensin receptor (AT-R) – antagonists had signifi-
cantly higher sRAGE and esRAGE levels (1370 vs. 997 pg/
ml, p < 0.01 and 278 vs. 198 pg/ml, p < 0.01) [15]. Hence,
additional multivariate models including sRAGE/esRAGE
as dependent variables and age, 24 hour albumin excre-
tion, glomerular filtration as well as ACE – inhibitor/AT-R
antagonist treatment were performed. In these models,
sRAGE showed marginally significant independent associ-
ations with age (β = 0.23, p = 0.05) and 24 hour albumin
excretion (β = 0.18, p = 0.05) while esRAGE was inde-
pendently associated with age only (β = 0.23, p = 0.05).
Conclusion
In this first comparative study of sRAGE and esRAGE as
markers of disease in type 2 diabetes, esRAGE concentra-
tions were found to be ~ 5 times lower than total sRAGE
concentrations, but correlated significantly with sRAGE.
In the multivariate regression model mentioned above,
esRAGE explained one third of the variation in sRAGE
found in our cohort suggesting diverse mechanisms lead-
ing to appearence of sRAGE and esRAGE in the circula-
tion. sRAGE is most likely cleaved from the cell surface by
action of matrix metalloproteinase 9 [1,8], which is
known to be upregulated and precedes the development
of albuminuria in patients with T2DM [16]. Consistently
and in line with previous data [4,17], we found a weak but
independent association of sRAGE with albuminuria in
the multivariate model with gender being the only addi-
tional independent variable influencing sRAGE levels.
There were no associations of esRAGE with the albumin
excretion rate. In view of the findings that AGEs induce
the expression of RAGE [18] and that serum AGEs corre-
late positively with AGEs in T2DM [17], an increase in
AGEs might also cause an upregulation of esRAGE. Hence,
our finding of an independent positive association of
esRAGE with age (Table 1) could be consequence of an
increased AGE-load during aging [19-21]. Interestingly,
soluble RAGE itself might be capable of triggering inflam-
matory reactions via binding of Mac1 and subsequent
activation of NF-κB and thus contribute to the develop-
ment of vascular complications [22].
The divergent data concerning associations of sRAGE and
esRAGE with markers of glucose control and vascular risk
in our cohort and published cross-sectional studies are
likely to be a consequence of the study designs applied.
Inverse associations of sRAGE with IMT and coronary
artery disease were previously described in non-diabetic
and diabetic cohorts [6,23] and are not evident in our
T2DM patients. The inverse correlation of esRAGE or
sRAGE with the HbA1c reported in patients with type 1
diabetes [5,6] and T2DM [2] as well as the weak associa-
tions of esRAGE with IMT [6] might partly be a conse-
quence of analyses in mixed cohorts of healthy volunteers
and patients with diabetes. This leads to a bias when dia-
betes is not entered as an additional variable in multivar-
iate models and is especially true, when significant
differences in esRAGE levels are evident between diabetes
patients and healthy controls [6]. Consistently, these data
cannot be reproduced in this study and previous publica-
tions [4,17] analysing patients with T2DM separately. As
previously shown in patients with type 1 diabetes [15],
sRAGE and esRAGE levels were increased in our type 2
diabetes patients. This might either be a consequence of
direct effects of ACE – inhibitors or AT-R antagonists on
sRAGE secretion (which was shown in bovine endothelial
Table 1: Patient characteristics and associations of sRAGE and esRAGE with different variables in 110 patients with type 2 diabetes
sRAGE# esRAGE#
Characteristics univariate (R) multivariate (β) univariate (R) multivariate (β)
Age (years) 59 ± 7 0.22* - 0.23* 0.24**
Gender (f/m) 24/86 - 0.21* - -
Diabetes duration (years) 13 ± 8 0.11 - 0.11 -
BMI (kg/m2) 33 ± 6 0.04 - -0.04 -
HbA1c (%) 7.4 ± 1.2 -0.02 - 0.05 -
Fasting glucose (mmol/l) 8.2 ± 3.0 0.05 - 0.05 -
Glomerular filtration rate (ml/min) 128 ± 50 -0.15 - -0.14 -
mean 24 h systolic BP (mmHg) 141 ± 16 0.02 - -0.06 -
mean 24 h diastolic BP (mmHg) 80 ± 8 -0.14 - -1.8 -
24 h Albumin excretion (mg)# 170 ± 406 0.18* 0.22* 0.10 -
Macrovascular Complications (%) 33
Retinopathy (%) 27
Polyneuropathy (%) 52
Insulin therapy (%) 64
ACE-Inhibitors/AT-R antagonists (%) 88
Data is given as mean ± SD. R = Spearman correlation coefficient. β = standardized coefficient as given by stepwise multivariate regression analysis. 
# = variables were not normally distributed and log-transformed for multivariate analysis. * p ≤ 0.05, ** p ≤ 0.01Cardiovascular Diabetology 2007, 6:9 http://www.cardiab.com/content/6/1/9
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cells in vitro [15]) or a RAGE-ligand dependent induction
of esRAGE.
It cannot be excluded that significant correlations of
sRAGE or esRAGE with IMT or glucose control can be
found in larger groups, a valuable biomarker would how-
ever be expected to show associations even in smaller
cohorts like the T2DM patients presented herein. The
results argue for a distinct role of sRAGE and esRAGE as
potential markers in diabetes: while total sRAGE indicates
microvascular damage, plasma esRAGE is not associated
with any markers of disease in T2DM. Prospective clinical
trials will have to define the impact of sRAGE as a marker
of cardiovascular risk in diabetes mellitus.
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